FIELD: medicine; pharmaceutics.
SUBSTANCE: invention refers to medicine, namely to a pharmaceutical composition possessing anti-stroke action. Composition contains in equal weight fractions lithium salts of substrates of the Krebs cycle, such as lithium pyruvate, lithium citrate, lithium succitate, lithium oxalo-acetate, lithium malate and lithium fumarate. Proposed composition has pronounced anti-stroke action, which consists in reduction of cerebral infarction area with ischemic injury.
EFFECT: wider range of products having anti-stroke action.
1 cl, 1 dwg, 1 ex
Title | Year | Author | Number |
---|---|---|---|
COMPOSITION WITH A GEROPROTECTOR EFFECT | 2021 |
|
RU2770515C1 |
AGENT WITH ANTI-STROKE ACTION | 2018 |
|
RU2675601C1 |
AGENT FOR PREVENTING AND TREATING NEURODEGENERATIVE PATHOLOGY AND VASCULAR DEMENTIA (VERSIONS) | 2014 |
|
RU2582962C1 |
LITHIUM-CONTAINING AGENT TO PREVENT AND TREAT CEREBROVASCULAR DISEASES AND METHOD OF APPLICATION THEREOF | 2008 |
|
RU2367427C1 |
MEANS FOR ISCHEMIA TREATMENT, METHOD FOR ITS PRODUCTION AND METHOD FOR ISCHEMIA TREATMENT (VERSIONS) | 2015 |
|
RU2620163C2 |
METHOD FOR PREVENTING AND TREATING NEURODEGENERATIVE PATHOLOGY AND VASCULAR DEMENTIA | 2014 |
|
RU2587617C1 |
CARDIOPROTECTIVE, ANTIARRHYTHMIC ANTI-ISHEMIC AGENT | 2007 |
|
RU2366426C2 |
COMBINED DRUG FOR PRIMARY NEUROPROTECTION | 2017 |
|
RU2636616C1 |
AGENT WITH NEUROPROTECTIVE ACTIVITY | 2019 |
|
RU2800955C2 |
NEUROPROTECTIVE ACTION OF SOLUBLE URSODEOXYCHOLIC ACID IN MODELS OF FOCAL ISCHEMIA | 2005 |
|
RU2428987C2 |
Authors
Dates
2020-12-02—Published
2020-05-13—Filed